An Open-Label Phase II Study of Capecitabine in Combination With Pegylated Interferon Alfa-2a in Patients With Advanced Hepatocellular Carcinoma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Peginterferon alfa-2a
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Roche
- 08 Dec 2008 Status changed from active, no longer recruiting to completed.
- 01 Jun 2006 New trial record.